



## COMPANY OVERVIEW

Cerecor is a biopharmaceutical company developing innovative therapies at the cutting edge of science. Our pipeline, filled with forward-thinking ideas, propels us forward. We are driven to change the lives of patients with rare pediatric and orphan diseases.

## RECENT NEWS

### Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

Jul 26 2021, 4:01 PM EDT

### Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets

Jun 23 2021, 7:30 AM EDT

## STOCK OVERVIEW

Symbol	CERC
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week Range	\$ - \$

## INVESTOR RELATIONS

[ir@cerecor.com](mailto:ir@cerecor.com)

## MANAGEMENT TEAM

### Michael Cola

Chief Executive Officer and Chairman of the Board

### Schond L. Greenway

Chief Financial Officer

### James A. Harrell, Jr.

Chief Commercial Officer

### Dr. Garry Neil, MD

Chief Scientific Officer

### Younok Dumortier Shin, PhD, MBA

Chief Technology Officer

### Chris Sullivan

Chief Accounting Officer

### H. Jeffrey Wilkins, MD

Chief Medical Officer

### Lisa Hegg Ph.D.

Vice President Research and Development Programs and Project Management

### Colleen Matkowski

Vice President Global Regulatory Affairs

---

## CERECOR, INC.

540 Gaither Road  
Suite 400  
Rockville, MD 20850

---

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.